This Week in Cardiology Sep 05 2025 This Week in Cardiology
55 snips
Sep 5, 2025 Explore the evolving role of beta-blockers after myocardial infarction and the latest insights from the ESC conference. Tune in for discussions on dual pathway therapy combining aspirin and oral anticoagulants, which might pose significant risks. Learn about the implications of stopping oral anticoagulants post-AF ablation and the notable findings from the DANCAVAS II trial. The conversation emphasizes evidence-based practices and the importance of continued research in cardiology.
AI Snips
Chapters
Transcript
Episode notes
CAC0 Listener Pushback And Clinician Example
- John Mandrola recounts two listener responses about CAC0 and LDL that changed his framing of the test's use.
- One critic called his headline sensationalist while a Portuguese cardiologist offered practical LDL-target examples tied to CAC scores.
Rethinking Routine Beta Blockers After MI
- Contemporary pragmatic trials show routine post-MI beta blockers no longer have robust evidence of benefit.
- John argues guidelines and quality mandates for routine post-MI beta blockers should be reversed given modern revascularization and trial results.
Aspirin Plus OAC Raises Harm After PCI
- The AQUATIC trial found adding aspirin to oral anticoagulation increased death and major bleeding in patients with prior PCI.
- Dual pathway therapy (anticoagulant plus aspirin) proved clearly worse than anticoagulation alone in this high-risk cohort.